HRTX logo

HRTXHeron Therapeutics Inc

$0.403
$0.0035
(0.86%)
Today
Closed $0.4084
$0.0054
(1.32%)
After Hours
Updated: 06:13 PM EDT
Reported EarningsMay 11
Mkt Cap$76.64M
Vol4.11M
News
all
press releases
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Stocktwits
News Placeholder
More News
News Placeholder
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright...
Yahoo! Finance: News
News Placeholder
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
News Placeholder
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -0.86% and +7.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Heron Therapeutics (HRTX) Expected to Announce Quarterly Earnings on Tuesday
Heron Therapeutics (NASDAQ:HRTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.